Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Preaxia Health Care Payment Systems (PAXH) Research & Development (2019 - 2025)

Preaxia Health Care Payment Systems' Research & Development history spans 7 years, with the latest figure at $391263.0 for Q3 2025.

  • On a quarterly basis, Research & Development changed N/A to $391263.0 in Q3 2025 year-over-year; TTM through Nov 2025 was $391263.0, a 20151.71% increase, with the full-year FY2024 number at $5632.0, down 13.73% from a year prior.
  • Research & Development hit $391263.0 in Q3 2025 for Preaxia Health Care Payment Systems, up from -$504.0 in the prior quarter.
  • Over the last five years, Research & Development for PAXH hit a ceiling of $391263.0 in Q3 2025 and a floor of -$504.0 in Q2 2024.
  • Historically, Research & Development has averaged $28924.1 across 5 years, with a median of $2081.0 in 2021.
  • The widest YoY moves for Research & Development: up 556.6% in 2024, down 138.39% in 2024.
  • Tracing PAXH's Research & Development over 5 years: stood at $2073.0 in 2021, then fell by 24.12% to $1573.0 in 2022, then surged by 38.53% to $2179.0 in 2023, then plummeted by 123.13% to -$504.0 in 2024, then surged by 77731.55% to $391263.0 in 2025.
  • Business Quant data shows Research & Development for PAXH at $391263.0 in Q3 2025, -$504.0 in Q2 2024, and $2436.0 in Q1 2024.